Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i

Mailys Guillard, Yoshinao Wada, Hana Hansikova, Isao Yuasa, Katerina Vesela, Nina Ondruskova, MacHiko Kadoya, Alice Janssen, Lambertus P.W.J. Van Den Heuvel, Eva Morava-Kozicz, Jiri Zeman, Ron A. Wevers, Dirk J. Lefeber

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. Isoelectric focusing (IEF) of serum transferrin is the most common screening method to detect abnormalities of protein N-glycosylation. On the basis of the IEF profile, patients can be grouped into CDG type I or CDG type II. Several protein variants of transferrin are known that result in a shift in isoelectric point (pI). In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation. In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site. In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients. In case 2, a peptide with mutation p.Asn432His was found. These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I.

Original languageEnglish (US)
Pages (from-to)901-906
Number of pages6
JournalJournal of Inherited Metabolic Disease
Volume34
Issue number4
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Congenital Disorders of Glycosylation
Transferrin
Glycosylation
Isoelectric Focusing
Mutation
Peptides
Neuraminidase
Digestion
Mass Spectrometry
Isoelectric Point
Serum
Polysaccharides
Proteins
Lipids

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i. / Guillard, Mailys; Wada, Yoshinao; Hansikova, Hana; Yuasa, Isao; Vesela, Katerina; Ondruskova, Nina; Kadoya, MacHiko; Janssen, Alice; Van Den Heuvel, Lambertus P.W.J.; Morava-Kozicz, Eva; Zeman, Jiri; Wevers, Ron A.; Lefeber, Dirk J.

In: Journal of Inherited Metabolic Disease, Vol. 34, No. 4, 01.08.2011, p. 901-906.

Research output: Contribution to journalArticle

Guillard, M, Wada, Y, Hansikova, H, Yuasa, I, Vesela, K, Ondruskova, N, Kadoya, M, Janssen, A, Van Den Heuvel, LPWJ, Morava-Kozicz, E, Zeman, J, Wevers, RA & Lefeber, DJ 2011, 'Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i', Journal of Inherited Metabolic Disease, vol. 34, no. 4, pp. 901-906. https://doi.org/10.1007/s10545-011-9311-y
Guillard, Mailys ; Wada, Yoshinao ; Hansikova, Hana ; Yuasa, Isao ; Vesela, Katerina ; Ondruskova, Nina ; Kadoya, MacHiko ; Janssen, Alice ; Van Den Heuvel, Lambertus P.W.J. ; Morava-Kozicz, Eva ; Zeman, Jiri ; Wevers, Ron A. ; Lefeber, Dirk J. / Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i. In: Journal of Inherited Metabolic Disease. 2011 ; Vol. 34, No. 4. pp. 901-906.
@article{cd51e6adb1f44c8e8d747cc751871211,
title = "Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i",
abstract = "Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. Isoelectric focusing (IEF) of serum transferrin is the most common screening method to detect abnormalities of protein N-glycosylation. On the basis of the IEF profile, patients can be grouped into CDG type I or CDG type II. Several protein variants of transferrin are known that result in a shift in isoelectric point (pI). In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation. In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site. In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients. In case 2, a peptide with mutation p.Asn432His was found. These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I.",
author = "Mailys Guillard and Yoshinao Wada and Hana Hansikova and Isao Yuasa and Katerina Vesela and Nina Ondruskova and MacHiko Kadoya and Alice Janssen and {Van Den Heuvel}, {Lambertus P.W.J.} and Eva Morava-Kozicz and Jiri Zeman and Wevers, {Ron A.} and Lefeber, {Dirk J.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1007/s10545-011-9311-y",
language = "English (US)",
volume = "34",
pages = "901--906",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Transferrin mutations at the glycosylation site complicate diagnosis of congenital disorders of glycosylation type i

AU - Guillard, Mailys

AU - Wada, Yoshinao

AU - Hansikova, Hana

AU - Yuasa, Isao

AU - Vesela, Katerina

AU - Ondruskova, Nina

AU - Kadoya, MacHiko

AU - Janssen, Alice

AU - Van Den Heuvel, Lambertus P.W.J.

AU - Morava-Kozicz, Eva

AU - Zeman, Jiri

AU - Wevers, Ron A.

AU - Lefeber, Dirk J.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. Isoelectric focusing (IEF) of serum transferrin is the most common screening method to detect abnormalities of protein N-glycosylation. On the basis of the IEF profile, patients can be grouped into CDG type I or CDG type II. Several protein variants of transferrin are known that result in a shift in isoelectric point (pI). In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation. In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site. In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients. In case 2, a peptide with mutation p.Asn432His was found. These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I.

AB - Congenital disorders of glycosylation (CDG) form a group of metabolic disorders caused by deficient glycosylation of proteins and/or lipids. Isoelectric focusing (IEF) of serum transferrin is the most common screening method to detect abnormalities of protein N-glycosylation. On the basis of the IEF profile, patients can be grouped into CDG type I or CDG type II. Several protein variants of transferrin are known that result in a shift in isoelectric point (pI). In some cases, these protein variants co-migrate with transferrin glycoforms, which complicates interpretation. In two patients with abnormal serum transferrin IEF profiles, neuraminidase digestion and subsequent IEF showed profiles suggestive of the diagnosis of CDG type I. Mass spectrometry of tryptic peptides of immunopurified transferrin, however, revealed a novel mutation at the N-glycan attachment site. In case 1, a peptide with mutation p.Asn630Thr in the 2nd glycosylation site was identified, resulting in an additional band at disialotransferrin position on IEF. After neuraminidase digestion, a single band was found at the asialotransferrin position, indistinguishable from CDG type I patients. In case 2, a peptide with mutation p.Asn432His was found. These results show the use of mass spectrometry of transferrin peptides in the diagnostic track of CDG type I.

UR - http://www.scopus.com/inward/record.url?scp=79961168906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961168906&partnerID=8YFLogxK

U2 - 10.1007/s10545-011-9311-y

DO - 10.1007/s10545-011-9311-y

M3 - Article

VL - 34

SP - 901

EP - 906

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 4

ER -